2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Metastatic Breast Cancer|Recurrent Breast Cancer
Interventions: DRUG: Experimental Arm A: Pemetrexed|DRUG: Experimental Arm A: Sorafenib|DRUG: Experimental Arm B: Pemetrexed|DRUG: Experimental Arm B: Sorafenib
Sponsor: Virginia Commonwealth University
Collaborators: Eli Lilly and Company|Bayer